Medicine RSS Search Engine

Cilostazol

This page shows you the latest news and research items in this category.

The Limits of Evidence in Drug Approval and Availability: A Case Study of Cilostazol and Naftidrofuryl for the Treatment of Intermittent Claudication.
This article provides an overview of the pharmacology of cilostazol and naftidrofuryl, and the clinical studies leading to their approval and clinical acceptance. It further explores the possible sources of bias in analyzing these clinical trials, some of which have been brought to light by the National Institute for Health and Clinical Excellence (NICE) of the United Kingdom in its technology appraisal guidance. It also speculates the ways in which economic incentives may affect drug-marketing decisions. METHODS: A literature review of pharmacology and clinical trials for cilostazol and naftidrofuryl was performed in ...
Source: Clinical Therapeutics - July 7, 2014 Category: Drugs & Pharmacology Authors: Hong H, Mackey WC Tags: Clin Ther Source Type: research

Healthcare Quality Indicators of Peripheral Artery Disease Based on Systematic Reviews
Conclusions: These quality indicators will help clinicians to assess the appropriateness of healthcare provided in PAD. The development of evidence-based indicators in PAD is limited by the lack of methodological quality of the research in this disease, the inconclusiveness of the evidence on diagnostic and surgical techniques, and the dynamic nature of the vascular diseases field. (Source: European Journal of Vascular and Endovascular Surgery)
Source: European Journal of Vascular and Endovascular Surgery - June 16, 2014 Category: Surgery Authors: S. Bellmunt, M. Roqué, D. Osorio, H. Pardo, J.-R. Escudero, X. Bonfill Tags: Peripheral Arterial Disease Source Type: research

Cilostazol suppresses β‐amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1‐coupled retinoic acid receptor‐β
In conclusion, cilostazol suppresses the accumulations of FL‐APP and Aβ by activating ADAM10 via the upregulation of SIRT1‐coupled RARβ. © 2014 Wiley Periodicals, Inc. (Source: Journal of Neuroscience Research)
Source: Journal of Neuroscience Research - June 5, 2014 Category: Neuroscience Authors: Hye Rin Lee, Hwa Kyoung Shin, So Youn Park, Hye Young Kim, Won Suk Lee, Byung Yong Rhim, Ki Whan Hong, Chi Dae Kim Tags: Research Article Source Type: research

Cilostazol and outcome in outpatients with peripheral artery disease
(Source: Thrombosis Research)
Source: Thrombosis Research - June 5, 2014 Category: Hematology Authors: Paulina Perez, Carlos Esteban, Joan Carles Sauquillo, Monserrat Yeste, Luis Manzano, Abel Mujal, Pedro Enrique Jiménez Caballero, Eduardo Aguilar, Juan Francisco Sánchez Muñoz-Torrero, Manuel Monreal, the FRENA Investigators Source Type: research

Surgeon Still a Step Behind Medicine: Indicators of Healthcare for Peripheral Artery Disease
Patients with peripheral arterial disease (PAD) currently have a range of therapies that might improve outcomes, including supervised exercise programs, medications, endovascular procedures, and surgery. An appropriate clinical approach to PAD could decrease morbidity and mortality, reduce the risk of amputation, and increase patients' functional status and quality of life. Nevertheless, in clinical practice significant judgment by the physician to adapt the variety of treatments available to the care of each individual patient with PAD is often required with uncertain and often unsatisfactory effects on outcomes. Even tho...
Source: European Journal of Vascular and Endovascular Surgery - May 22, 2014 Category: Surgery Authors: P. De Rango Tags: Invited Commentary Source Type: research

Abnormal Repolarization as the Basis for Late Potentials and Fractionated Electrograms Recorded From Epicardium in Experimental Models of Brugada Syndrome
ConclusionsThese data point to an alternative pathophysiological basis for late potentials and fractionated electrical activity recorded in the right ventricle in the setting of BrS. We demonstrate an association of such activity with abnormal repolarization and not with abnormal depolarization or structural abnormalities. (Source: Journal of the American College of Cardiology: Cardiovascular Interventions)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - May 12, 2014 Category: Cardiology Source Type: research

Three types of ependymal cells with intracellular calcium oscillation are characterized by distinct cilia beating properties
Ependymal cells are multiciliated epithelial cells that line the ventricles in the adult brain. Abnormal function or structure of ependymal cilia has been associated with various neurological deficits. For the first time, we report three distinct ependymal cell types, I, II, and III, based on their unique ciliary beating frequency and beating angle. These ependymal cells have specific localizations within the third ventricle of the mouse brain. Furthermore, neither ependymal cell types nor their localizations are altered by aging. Our high‐speed fluorescence imaging analysis reveals that these ependymal cells have an int...
Source: Journal of Neuroscience Research - May 10, 2014 Category: Neuroscience Authors: Tongyu Liu, Xingjian Jin, Rahul M. Prasad, Youssef Sari, Surya M. Nauli Tags: Research Article Source Type: research

Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes
(Source: Heart Rhythm)
Source: Heart Rhythm - May 6, 2014 Category: Cardiology Authors: Tetsuji Shinohara, Yuki Ebata, Reika Ayabe, Akira Fukui, Norihiro Okada, Kunio Yufu, Mikiko Nakagawa, Naohiko Takahashi Source Type: research

Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics
ConclusionEndoscopic biopsy did not increase the bleeding risk despite not stopping antithrombotics prior to biopsy even among patients taking warfarin whose PT‐INR was within the therapeutic range. (Source: Digestive Endoscopy)
Source: Digestive Endoscopy - April 28, 2014 Category: Gastroenterology Authors: Minoru Fujita, Akiko Shiotani, Takahisa Murao, Manabu Ishii, Yoshiyuki Yamanaka, Rui Nakato, Hiroshi Matsumoto, Ken‐ichi Tarumi, Noriaki Manabe, Tomoari Kamada, Jiro Hata, Ken Haruma Tags: Original Article Source Type: research

Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy
Conclusion: The results of the present study highlight that clopidogrel and cilostazol combination therapy may be considered to be an alternative method for treating patients with CLI unsuitable for surgical revascularization or PTA. (Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - April 17, 2014 Category: Research Authors: Jiunn-Jye SheuPao-Yuan LinPei-Hsun SungYi-Ching ChenSteve LeuYung-Lung ChenTzu-Hsien TsaiHan-Tan ChaiSarah ChuaHsueh-Wen ChangSheng-Ying ChungChih-Hung ChenSheung-Fat KoHon-Kan Yip Source Type: research

Cilostazol induces mitochondrial fatty acid β-oxidation in C2C12 myotubes.
In this study, we report that cilostazol can elevate complete FAO and decrease both triacylglycerol (TAG) accumulation and TAG secretion. This use of cilostazol treatment increases expression of PGC-1α and, subsequently, its target genes, such as ERRα, NOR1, CD36, CPT1, MCAD, and ACO. Expression of these factors is linked to fatty acid β-oxidation but this effect is inhibited by H-89, a specific inhibitor of the PKA/CREB pathway. Importantly, knockdown of PGC-1α using siRNA abolished the effects of cilostazol in fatty acid oxidation (FAO) and TAG metabolism. These findings suggested that the PKA/CREB/PGC-1α pathway pl...
Source: Biochemical and Biophysical Research communications - April 11, 2014 Category: Biochemistry Authors: Wang B, Zhu L, Sui S, Sun C, Jiang H, Ren D Tags: Biochem Biophys Res Commun Source Type: research

Colonic diverticular hemorrhage associated with the use of NSAIDs, low‐dose aspirin, antiplatelet drugs, and dual therapy
ConclusionsBesides alcohol and smoking, NSAIDs, low‐dose aspirin, and antiplatelet drugs are risk factors for diverticular bleeding. The magnitude of risk may differ between different kinds of NSAIDs and antiplatelet drugs, and dual therapy with NSAIDs or antiplatelet drugs increases the risk of bleeding. (Source: Journal of Gastroenterology and Hepatology)
Source: Journal of Gastroenterology and Hepatology - April 10, 2014 Category: Gastroenterology Authors: Naoyoshi Nagata, Ryota Niikura, Tomonori Aoki, Takuro Shimbo, Yoshihiro Kishida, Katsunori Sekine, Shohei Tanaka, Kazuhiro Watanabe, Toshiyuki Sakurai, Chizu Yokoi, Junichi Akiyama, Mikio Yanase, Masashi Mizokami, Naomi Uemura Tags: Clinical Gastroenterology Source Type: research

Cilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation.
Conclusions: Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking. PMID: 24694769 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - April 3, 2014 Category: Cardiology Authors: Kim HL, Suh JW, Lee SP, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS Tags: Circ J Source Type: research

CILOSTAZOL Tablet [BIOKEY INC.]
Updated Date: Apr 1, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - April 1, 2014 Category: Drugs & Pharmacology Source Type: news

Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B
The lipid-lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of nonesterified fatty acids (NEFA) to the circulation. However, long-term niacin treatment leads to a normalization of plasma NEFA levels and induces insulin resistance, for which the underlying mechanisms are poorly understood. The current study addressed the effects of long-term niacin treatment on insulin-mediated inhibition of adipocyte lipolysis and focused on the regulation of cAMP levels. APOE*3-Leiden.CETP transgenic mice treated with niacin for 15 wk we...
Source: AJP: Endocrinology and Metabolism - April 1, 2014 Category: Endocrinology Authors: Heemskerk, M. M., van den Berg, S. A. A., Pronk, A. C. M., van Klinken, J.-B., Boon, M. R., Havekes, L. M., Rensen, P. C. N., van Dijk, K. W., van Harmelen, V. Tags: Articles Source Type: research

Cilostazol reduces morbidity but not mortality secondary to cerebral vasospasm following aneurysmal subarachnoid hemorrhage
I have read, with great interest, a recently published article in the Journal of the Neurological Sciences by Niu et al. titled ‘Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis’ . In this meta-analysis, the authors analyze the outcomes for 340 patients from four studies (two randomized and two quasi-randomized controlled trials) which evaluated the effect of cilostazol, a phosphodiesterase inhibitor 3 (PDE3) inhibitor, on cerebral vasospasm (CV) and overall outcomes following aneurysmal subarachnoid hemorrhage (aSAH). The total numbers of patients in the c...
Source: Journal of the Neurological Sciences - March 31, 2014 Category: Neurology Authors: Dale Ding Tags: Letters to the Editor Source Type: research

Semi‐Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Antiplatelet Agents
We examined the relationships between plasma concentrations of antiplatelet agents (triflusal, clopidogrel and cilostazol) and the platelet aggregation inhibitory effect after dosing. We used triflusal, cilostazol and clopidogrel for the development of a semi‐mechanistic PK/PD model. The drugs chosen are used widely and reflect various mechanisms of antiplatelet agents. Time courses of plasma concentrations of the antiplatelet agents and their platelet aggregation effects were analysed using ADPAT V. Pharmacokinetic profiles were fitted to an extended parent–metabolite pharmacokinetic model, based on a two‐compartmen...
Source: Basic and Clinical Pharmacology and Toxicology - March 29, 2014 Category: Drugs & Pharmacology Authors: Hwi‐yeol Yun, Wonku Kang, Byung‐yo Lee, Sunkyung Park, Young‐Ran Yoon, Jin Yeul Ma, Kwang‐il Kwon Tags: Original Article Source Type: research

Healthcare Quality Indicators of Peripheral Artery Disease Based on Systematic Reviews.
CONCLUSIONS: These quality indicators will help clinicians to assess the appropriateness of healthcare provided in PAD. The development of evidence-based indicators in PAD is limited by the lack of methodological quality of the research in this disease, the inconclusiveness of the evidence on diagnostic and surgical techniques, and the dynamic nature of the vascular diseases field. PMID: 24650396 [PubMed - as supplied by publisher] (Source: PubMed: Eur J Vasc Endovasc ...)
Source: PubMed: Eur J Vasc Endovasc ... - March 17, 2014 Category: Surgery Authors: Bellmunt S, Roqué M, Osorio D, Pardo H, Escudero JR, Bonfill X Tags: Eur J Vasc Endovasc Surg Source Type: research

Effect of Cilostazol Prescribed in a Pragmatic Treatment Program for Intermittent Claudication
Conclusion: Despite minimal behavior modification, up to 70% of patients taking cilostazol report an improvement in claudication symptoms with few side effects. (Source: Vascular and Endovascular Surgery)
Source: Vascular and Endovascular Surgery - March 5, 2014 Category: Surgery Authors: Lee, C., Nelson, P. R. Tags: Articles Source Type: research

Effects of Chronic Treatment With Cilostazol, a Phosphodiesterase 3 Inhibitor, on Female Rat Bladder in a Partial Bladder Outlet Obstruction Model
Conclusion: PDE3i has a small but significant protective effect on the contractile dysfunction induced by a 4-week BOO in rats, although the increase in bladder mass was not altered. PDE3i could be a useful protection against contractile dysfunction of the obstructed bladder. (Source: Urology)
Source: Urology - February 27, 2014 Category: Urology & Nephrology Authors: Seiji Matsumoto, Masaki Watanabe, Kazumi Hashizume, Naoki Wada, Jun-ichi Hori, Masafumi Kita, Tatsuya Iwata, Hidehiro Kakizaki Tags: Basic and Translational Science Source Type: research

Semi‐Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Anti‐Platelet Agents
This article is protected by copyright. All rights reserved. (Source: Basic and Clinical Pharmacology and Toxicology)
Source: Basic and Clinical Pharmacology and Toxicology - February 24, 2014 Category: Drugs & Pharmacology Authors: Hwi‐yeol Yun, Wonku Kang, Byung‐yo Lee, Sunkyung Park, Young‐Ran Yoon, Kwang‐il Kwon Tags: Original Article Source Type: research

Homocysteine as a Predictor of Early Neurological Deterioration in Acute Ischemic Stroke [Brief Reports]
Conclusions— Patients with acute stroke with elevated serum homocysteine levels are at an increased risk for END. (Source: Stroke)
Source: Stroke - February 24, 2014 Category: Neurology Authors: Kwon, H.-M., Lee, Y.-S., Bae, H.-J., Kang, D.-W. Tags: Risk Factors, Epidemiology Brief Reports Source Type: research

A Systematic Approach to Design and Prepare Solid Dispersions of Poorly Water-Soluble Drug.
The objective of the present study was to define a systematic approach to design and prepare solid dispersions of poorly water-soluble drug. The systematic approach can be defined in four phases. In the first phase, glass forming ability is assessed, and in the second phase, probable excipients are screened. The screened excipients are evaluated (third phase) for glass transition temperatures (T g) and miscibility studies according to Florey-Huggins interaction parameter. The predicted excipients are used to prepare the solid dispersion and evaluated for T g and any interactions using Fourier transfer infrared studies (fou...
Source: AAPS PharmSciTech - February 22, 2014 Category: Drugs & Pharmacology Authors: Verma S, Rudraraju VS Tags: AAPS PharmSciTech Source Type: research

Prospective Registry of Carotid Artery Stenting in Japan—Investigation on Device and Antiplatelet for Carotid Artery Stenting
Background: Carotid artery stenting (CAS) is minimally invasive but may cause perioperative cerebral infarction associated with distal embolization. We conducted a multicenter prospective observational study on the onset of vascular events after CAS to find out the efficacy and safety of CAS in Japan and to investigate the effects of antiplatelet drugs administered before and after CAS on efficacy and safety of CAS.Methods: A total of 949 patients with cervical carotid artery stenosis were enrolled at 43 institutions in Japan; 934 who had undergone CAS with antiplatelet drugs and followed for 1 year were analyzed. Primary ...
Source: Journal of Stroke and Cerebrovascular Diseases - February 19, 2014 Category: Neurology Authors: Nobuyuki Sakai, Hiroshi Yamagami, Yoshihiro Matsubara, Masayuki Ezura, Akio Hyodo, Yuji Matsumaru, Shigeru Miyachi, Yasushi Okada, Tomoaki Terada, Hiroyoshi Yokoi, Mitusugu Nakamura, Yasushi Matsumoto, Chiaki Sakai, IDEALCAST Investigators Tags: Original Articles Source Type: research

Cellular Mechanism Underlying Hypothermia-Induced Ventricular Tachycardia/Ventricular Fibrillation in the Setting of Early Repolarization and the Protective Effect of Quinidine, Cilostazol, and Milrinone [Original Articles]
Conclusions— Hypothermia leads to VT/VF in the setting of ER by exaggerating repolarization abnormalities, leading to development of phase 2 reentry. Quinidine, cilostazol, and milrinone suppress the hypothermia-induced VT/VF by reversing the repolarization abnormalities. (Source: Circulation: Arrhythmia and Electrophysiology)
Source: Circulation: Arrhythmia and Electrophysiology - February 18, 2014 Category: Cardiology Authors: Gurabi, Z., Koncz, I., Patocskai, B., Nesterenko, V. V., Antzelevitch, C. Tags: Arrythmias-basic studies Original Articles Source Type: research

The Effect of Acute Medication with Cilostazol, an Anti-platelet Drug, on the Outcome of Small Vessel Brain Infarction
In conclusion, cilostazol reduced the risk of early neurologic deterioration of patients with small vessel brain infarction. It is eagerly desired to conduct a large randomized control trial. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - February 10, 2014 Category: Neurology Authors: Taizen Nakase, Masahiro Sasaki, Akifumi Suzuki Tags: Original Articles Source Type: research

Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells
Conclusion: Cilostazol promoted growth of human LECs and improved lymph flow and lymphedema in two different mouse lymphedema models. These results suggest that cilostazol would be a promising agent for the treatment of lymphedema. (Source: Journal of Dermatological Science)
Source: Journal of Dermatological Science - February 10, 2014 Category: Dermatology Authors: Takayuki Kimura, Tatsuo S. Hamazaki, Makoto Sugaya, Shoji Fukuda, Techuan Chan, Miwa Tamura-Nakano, Shinichi Sato, Hitoshi Okochi Tags: Regular Articles Source Type: research

Effects of Cilostazol on Oxidative Stress, Systemic Cytokine Release, and Spinal Cord Injury in a Rat Model of Transient Aortic Occlusion
Conclusion: The present experimental study indicated that cilostazol pretreatment used in this study before aortic occlusion decreased lipid peroxidation, which may be related to the reduction of reactive oxygen species. Cilostazol did not significantly suppress systemic cytokine release and prevent spinal cord inflammation and injury; however, it did show some benefit. Additional investigations might be needed to determine the critical dose of cilostazol for clarifying the protective role of this drug in spinal cord ischemia/reperfusion injury. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - February 1, 2014 Category: Surgery Authors: Tunay Kurtoglu, Harun Basoglu, Erdem Ali Ozkisacik, Nesibe Kahraman Cetin, Canten Tataroglu, Cigdem Yenisey, Berent Discigil Tags: Basic Science Source Type: research

Cilostazol: same evidence, different conclusions.
PMID: 24493552 [PubMed - in process] (Source: Chest)
Source: Chest - February 1, 2014 Category: Respiratory Medicine Authors: Bellmunt S, Alonso-Coello P Tags: Chest Source Type: research

Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease
We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management. A Markov decision model was developed to assess the lifetime costs and benefits of each vasoactive drug compared to no vasoactive drug and with each other. Regression analysis was undertaken to model the relationship between maximum walking distance and utility. Resource use data were sourced from the literature and sensitivity analyses were undertaken. Naftidrofuryl oxalate is more ef...
Source: Angiology - January 30, 2014 Category: Cardiology Authors: Meng, Y., Squires, H., Stevens, J. W., Simpson, E., Harnan, S., Thomas, S., Michaels, J., Stansby, G., O'Donnell, M. E. Tags: Peripheral Arterial Disease Source Type: research

Cilostazol inhibits insulin-stimulated expression of sterol regulatory binding protein-1c via inhibition of LXR and Sp1.
Abstract Hepatic steatosis is common in obese individuals with hyperinsulinemia and is an important hepatic manifestation of metabolic syndrome. Sterol regulatory binding protein-1c (SREBP-1c) is a master regulator of lipogenic gene expression in the liver. Hyperinsulinemia induces transcription of SREBP-1c via activation of liver X receptor (LXR) and specificity protein 1 (Sp1). Cilostazol is an antiplatelet agent that prevents atherosclerosis and decreases serum triglyceride levels. However, little is known about the effects of cilostazol on hepatic lipogenesis. Here, we examined the role of cilostazol in the reg...
Source: exp Mol Med - January 28, 2014 Category: Molecular Biology Authors: Jung YA, Kim HK, Bae KH, Seo HY, Kim HS, Jang BK, Jung GS, Lee IK, Kim MK, Park KG Tags: Exp Mol Med Source Type: research

Long term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive down-regulation of phosphodiesterase 3B.
Abstract The lipid lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of non-esterified fatty acids (NEFA) to the circulation. However, long term niacin treatment leads to a normalization of plasma NEFA levels and induces insulin resistance, for which the underlying mechanisms are poorly understood. The current study addressed the effects of long term niacin treatment on insulin-mediated inhibition of adipocyte lipolysis and focused on the regulation of cAMP levels. APOE*3-Leiden.CETP transgenic mice treated with n...
Source: Am J Physiol Endocri... - January 28, 2014 Category: Endocrinology Authors: Heemskerk MM, van den Berg SA, Pronk AC, Van Klinken J, Boon MR, Havekes LM, Rensen PC, Willems van Dijk K, van Harmelen V Tags: Am J Physiol Endocrinol Metab Source Type: research

Cilostazol is associated with improved outcomes after peripheral endovascular interventions
(Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - January 27, 2014 Category: Surgery Authors: Courtney J. Warner, Spencer W. Greaves, Robin J. Larson, David H. Stone, Richard J. Powell, Daniel B. Walsh, Philip P. Goodney Source Type: research

Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease
Substantial evidence has elucidated the significance of postnatal vasculogenesis for neovascularization and vascular remodeling by peripheral endothelial progenitor cells (EPCs) . Some exogenous factors have been reported to be beneficial in the EPC mechanisms of action, including vascular endothelial growth factor (VEGF), stromal cell-derived factor (SDF)-1α, adiponectin and thrombomodulin (TM) . The number and function of circulating EPCs have been reported to be inversely associated with the presence of coronary risk factors as well as the existence of atherosclerotic diseases . (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - January 21, 2014 Category: Cardiology Authors: Ting-Hsing Chao, Shih-Ya Tseng, I-Chih Chen, Yi-Shan Tsai, Yao-Yi Huang, Ping-Yen Liu, Horng-Yih Ou, Yi-Heng Li, Hua-Lin Wu, Chung-Lung Cho, Liang-Miin Tsai, Jyh-Hong Chen Tags: Online Letters to the Editor Source Type: research

Neurovascular protection of cilostazol in stroke‐prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation
This study sought to evaluate the effects of commonly used antiplatelet drugs on spontaneous cerebral infarction in relation to neurovascular protection associated with angiogenesis and pericyte proliferation. Stroke‐prone spontaneously hypertensive rats (SHR‐SP) were treated with vehicle, aspirin, clopidogrel, or cilostazol from 8 to 10 weeks of age. The interaction of neurovascular components among endothelial cells, pericytes, and astrocytic endfeet were immunohistochemically examined in brain sections. Angiogenesis associated with vascular endothelial growth factor receptor 2 (VEGFR2) and pericyte proliferation wer...
Source: Journal of Neuroscience Research - December 21, 2013 Category: Neuroscience Authors: Yoshio Omote, Kentaro Deguchi, Syoichiro Kono, Ning Liu, Wentao Liu, Tomoko Kurata, Toru Yamashita, Yoshio Ikeda, Koji Abe Tags: Research Article Source Type: research

In vitro effects of cilostazol, a phosphodiesterase 3A inhibitor, on mouse oocyte maturation and morphology.
This study was designed to investigate the potential inhibitory effects of CLZ on oocyte maturation and morphology in vitro Antral oocytes were recovered from hyperstimulated mice and allocated to 10 different CLZ concentrations (0.00-67.66μM). Oocytes were then assessed after 24 and 48h of incubation for maturation and morphology. Some of the evaluated CLZ concentrations (1.06-4.23μM) were made similar to those observed in human clinical trials. CLZ arrested oocyte maturation at the germinal vesicle (GV) stage at concentrations as low as 1.06μM (P<0.0001). A selective degenerative impact of CLZ targeting arrested oo...
Source: Clinical and Experimental Pharmacology and Physiology - December 17, 2013 Category: Drugs & Pharmacology Authors: Taiyeb AM, Dees WL, Ridha-Albarzanchi MT, Sayes CM, Kraemer DC Tags: Clin Exp Pharmacol Physiol Source Type: research

The Effect of Cilostazol on Carotid Intima–Media Thickness Progression in Patients with Symptomatic Intracranial Atherosclerotic Stenosis
Conclusion: Cilostazol has a beneficial effect in preventing the progression of CIMT in ischemic stroke patients. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - December 9, 2013 Category: Neurology Authors: Bum Joon Kim, Joung-Ho Rha, Seong Rae Kim, Dong-Eog Kim, Hahn Young Kim, Ju-Hun Lee, Hee-Joon Bae, Moon-Ku Han, Dong-Wha Kang, Disya Ratanakorn, Jong S. Kim, Sun U. Kwon Tags: Original Articles Source Type: research

Differential Effect of Phosphodiesterase-3 Inhibitors on Sympathetic Hyperinnervation in Healed Rat Infarcts.
Conclusions: Unlike milrinone, cilostazol has therapeutic neutrality in arrhythmias because of adenosine uptake inhibition, which antagonizes the PDE-3-induced increase of sympathetic reinnervation via mediation of an adenosine A1 receptor-mediated antioxidation. PMID: 24304537 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - December 4, 2013 Category: Cardiology Authors: Lee TM, Lin SZ, Chang NC Tags: Circ J Source Type: research

Cilostazol inhibits leukocyte-endothelial cell interactions in murine microvessels after transient bilateral common carotid artery occlusion.
Abstract Leukocyte behavior in the cerebral microvasculature following vessel occlusion has not been fully elucidated. The purpose of this study was to investigate the effects of cilostazol on leukocyte behavior (rolling and adhesion) in murine cerebral microvessels following transient bilateral carotid artery occlusion using intravital fluorescence microscopy. Four groups of mice were assigned: a sham group (n=16); an ischemia (induced by 15-min occlusion of bilateral common carotid arteries) and reperfusion (I/R) group (n=13); I/R+cilostazol (I/R+CZ3mg/kg) group (I/R after oral administration of cilostazol at 3mg...
Source: Brain Research - December 2, 2013 Category: Neurology Authors: Fukuoka T, Hayashi T, Hirayama M, Maruyama H, Tanahashi N Tags: Brain Res Source Type: research

Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
CONCLUSION: Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF). PMID: 24280344 [PubMed - as supplied by publisher] (Source: Perfusion)
Source: Perfusion - November 26, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Alizade E, Sahin M, Simsek Z, Açar G, Bulut M, Güler A, Avci A, Kalkan M, Pala S, Akçakoyun M, Esen A Tags: Perfusion Source Type: research

Preparation and Characterization of Microemulsion of Cilostazol for Enhancement of Oral Bioavailability.
In this study, Capmul MCM C8 (glycerol monocaprylate) based MEs containing Tween 20(polysorbate 20) and/or Labrafil M 1944(poly oxyglycerides) as surfactant(S) and Transcutol P(diethyl glycol monoethyl ether) as cosurfactant(CoS) were studied as potential delivery systems of cilostazol. A number of such systems were prepared containing different S:CoS ratios(1:1, 2:1 and 3:1) based on phase diagrams. Loading of cilostazol was selected as per solubilization capacity and were characterized for pH, viscosity, conductivity, particle size, zeta potential and % transmittance. The MEs systems were further investigated for chemica...
Source: Current Drug Delivery - November 26, 2013 Category: Drugs & Pharmacology Authors: Patel SG, Rajput SJ, Groshev A, Sutariya VB Tags: Curr Drug Deliv Source Type: research

Attenuation of β‐amyloid‐induced tauopathy via activation of CK2α/SIRT1: Targeting for cilostazol
In conclusion, increased cAMP‐dependent protein kinase‐linked CK2/SIRT1 expression by cilostazol can be a therapeutic strategy to suppress the tau‐related neurodegeneration in the AD brain. © 2013 Wiley Periodicals, Inc. (Source: Journal of Neuroscience Research)
Source: Journal of Neuroscience Research - November 19, 2013 Category: Neuroscience Authors: Hye Rin Lee, Hwa Kyoung Shin, So Youn Park, Hye Young Kim, Won Suk Lee, Byung Yong Rhim, Ki Whan Hong, Chi Dae Kim Tags: Research Article Source Type: research

Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis
Conclusions: Adjunctive cilostazol (triple antiplatelet therapy) in clopidogrel-resistant patients reduces the rate of clopidogrel resistance and suppresses new ischemic lesions without hemorrhagic complications, as compared with standard DAT. Antiplatelet management based on the evaluation of antiplatelet resistance would be required for prevention of perioperative thromboembolic complications in CAS. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - November 18, 2013 Category: Surgery Authors: Ichiro Nakagawa, Takeshi Wada, Hun Soo Park, Fumihiko Nishimura, Syuichi Yamada, Hiroyuki Nakagawa, Kimihiko Kichikawa, Hiroyuki Nakase Tags: Clinical research studies Source Type: research

Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Source: The British Journal of Surgery - November 17, 2013 Category: Surgery Authors: Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638). Tags: Br J Surg Source Type: research

Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Abstract The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length. PMID: 24227374 [PubMed - in process] (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - November 17, 2013 Category: Surgery Authors: Roset PN Tags: Br J Surg Source Type: research

Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638)
The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length. (Source: British Journal of Surgery)
Source: British Journal of Surgery - November 14, 2013 Category: Surgery Authors: P. N. Roset Tags: Your Views Source Type: research

Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638)
(Source: British Journal of Surgery)
Source: British Journal of Surgery - November 14, 2013 Category: Surgery Authors: J.W. Stevens, E. Simpson, S. Harnan, H. Squires, Y. Meng, S. Thomas, J. Michaels, G. Stansby Tags: Your Views Source Type: research

Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis
Abstract: Previous studies with small sample size have shown that cilostazol can reduce the risk of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH). The purpose of this study was to determine whether cilostazol is effective in patients with aneurysmal SAH. Studies investigating the effect of cilostazol in patients with aneurysmal SAH were identified using Embase.com without language or publication-type restrictions. We used the random-effect model to combine data. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated. Two randomized controlled trials and two quasi-randomized...
Source: Journal of the Neurological Sciences - November 11, 2013 Category: Neurology Authors: Peng-Peng Niu, Ge Yang, Ying-Qi Xing, Zhen-Ni Guo, Yi Yang Tags: Original Articles Source Type: research

Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention
BackgroundWe investigated the pharmacodynamic effect of cilostazol addition (100 mg twice, Triple) or clopidogrel doubling (150 mg daily, Double) on standard dual antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients with clopidogrel resistance undergoing a percutaneous coronary intervention. Methods and resultsThis was a prospective, randomized, cross-over platelet function study. Percent inhibition less than 20% was used as the cutoff value of clopidogrel resistance. After percutaneous coronary intervention, a total of 50 T2DM patients with clopidogrel resistance were assigned to receive cilostazol 100 mg twic...
Source: Coronary Artery Disease - November 8, 2013 Category: Cardiology Tags: Original Research Source Type: research

Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions: A Meta-Analysis
Conclusion: Addition of cilostazol to conventional dual antiplatelet therapy significantly lowers platelet reactivity and may explain a decrease in thromboembolic events following coronary intervention; however, additional studies evaluating clinical outcomes will be helpful to determine the benefit of triple antiplatelet therapy. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)
Source: Journal of Cardiovascular Pharmacology and Therapeutics - November 8, 2013 Category: Cardiology Authors: Panchal, H. B., Shah, T., Patel, P., Albalbissi, K., Molnar, J., Coffey, B., Khosla, S., Ramu, V. Tags: Clinical Studies Source Type: research